Chapter 3

Comparison of Survival Curves


3.1 Basis for Comparison of Survival Curves

We have examined some nonparametric approaches for estimating the survival function, $\hat{S}(t)$, over time for a single sample of individuals.

Now we want to compare the survival estimates between two groups. How can we compare the two estimated survival distributions, $\hat{S}_1(t)$ and $\hat{S}_2(t)$?

For example: Time to relapse of leukemia patients

Figure 3.1: Kaplan-Meier curves for both trt groups Leukemia study (Cox and Oakes)



Survival at a fixed time point

- Sometimes a specific time point, t^* , is of special interest e.g. 5-year disease-free survival in cancer
- At this specific time point, is there a difference in the true survival? We could evaluate this question using our data by checking whether the "pointwise*" confidence intervals for the survival curves overlap at t^* ?
- We can base a comparison on the approximate independent normal distributions of $\hat{S}_k(t^*)$; $k \in \{0,1\}$:
- In other words, we can check whether the 95% CI for the difference in survival estimates:

$$\left[\left(\hat{S}_1(t^*) - \hat{S}_0(t^*) \right) \pm 1.96 \times \sqrt{V_1(t^*) + V_0(t^*)} \right]$$

includes 0, where $V_k(t^*)$ is the estimated variance of $\hat{S}_k(t^*)$.

^{*} Note: The pointwise confidence intervals we have been calculating correspond to a CI for $\hat{S}(t^*)$ at a particular point in time, t^* . The issue of **confidence bands** for the entire estimated survival function are discussed in Section 4.4 of Klein and Moeschberger

Global comparisons of survival distributions

For testing

$$H_0: S_1(t) = S_0(t)$$
 for every value of t

Should we base the comparison on:

- the furthest distance between the two curves?
- the median survival for each group?
- the average hazard? (for exponential distributions, this would be like comparing the mean event times)
- adding up the difference between the two survival estimates over time?

$$\sum_{j} \left[\hat{S}(t_{jA}) - \hat{S}(t_{jB}) \right]$$

- a weighted sum of differences, where the weights reflect the number at risk at each time?
- a rank-based test? i.e., we could rank all of the event times, and then see whether the sum of ranks for one group was less than the other.

Nonparametric comparisons of groups

All of the above are pretty reasonable options, and there have been several proposals for how to compare the survival of two groups. For the moment, we are sticking to nonparametric comparisons.

Why nonparametric?

- fairly robust
- quite efficient relative to parametric tests
- often simple and intuitive

Before continuing the description of the two-sample comparison, we give a more general perspective within which this approach is framed.

3.2 General Framework for Survival Analysis

We observe $(X_i, \delta_i, \mathbf{Z}_i)$ for individual i, where

- X_i is a censored failure time random variable
- δ_i is the failure/censoring indicator
- \bullet **Z**_i represents a set of covariates

Note that Z_i might be:

- a scalar (a single covariate, say treatment or gender)
- \bullet or may be a $(p \times 1)$ vector (representing several different covariates).

These covariates might be:

- continuous
- discrete
- time-varying (more later)

If Z_i is a scalar and is binary, then we are comparing the survival of two groups, like in the leukemia example.

More generally though, it is useful to build a model that characterizes the relationship between survival and all of the covariates of interest.

3.2.1 Relationships between covariates and survival outcomes

The general framework allows us to proceed in several different directions, as we start to evaluate the relationship between covariates (treatments or exposures) and survival outcomes:

- Two group comparisons (e.g. logrank)
- Multigroup and stratified comparisons (e.g. stratified logrank)
- Failure time regression models
 - Cox proportional hazards model
 - Accelerated failure time model

3.3 Two sample tests for Comparing Survival

- Mantel-Haenszel logrank test
- Peto & Peto's version of the logrank test
- Gehan's Generalized Wilcoxon
- Peto & Peto's and Prentice's generalized Wilcoxon
- Tarone-Ware and Fleming-Harrington classes
- Cox's F-test (non-parametric version)

References:

Hosmer & Lemeshow	Section 2.4
Collett	Section 2.5
Klein & Moeschberger	Section 7.3
Kleinbaum	Chapter 2
Lee	Chapter 5

3.3.1 Mantel-Haenszel Logrank test

The logrank test is the most well known and widely used.

It has an intuitive appeal, building on standard methods for binary data. (Later we will see that it can be obtained as the score test from a Cox Proportional Hazards model.)

First consider the following (2×2) table classifying those with and without the event of interest in a two group setting:

Group	Yes	No	Total
0	d_0	$n_0 - d_0$	n_0
1	d_1	$n_1 - d_1$	n_1
Total	d	n-d	n

The previous table showed the observed numbers with and without events in each group, and the margin totals. But let's define D_0 as the random variable representing the number with an event in Group 0.

If the margins of this table $(d, n - d, n_0, n_1)$ are considered fixed, then D_0 follows a hypergeometric distibution, depending on 1 parameter (the population odds ratio, ψ).

Under the null hypothesis of no association between the event and group, it follows that:

$$E(D_0) = \frac{n_0 d}{n} = n_0 \left(\frac{d}{n}\right)$$

$$Var(D_0) = \frac{n_0 n_1 d(n-d)}{n^2(n-1)}$$

Therefore, under
$$H_0$$
: $\chi^2_{MH} = \frac{[D_0 - n_0 d/n]^2}{\frac{n_0 n_1 d(n-d)}{n^2(n-1)}} \sim \chi^2_1$

This is the Mantel-Haenszel statistic and is approximately equivalent to the Pearson χ^2 test for equality of the two groups given by:

$$\chi_p^2 = \sum \frac{(O-e)^2}{e}$$

3.3. TWO SAMPLE TESTS FOR COMPARING SURVIVAL

Example: Toxicity in a clinical trial with two treatments

Group	Yes	No	Total
0	8	42	50
1	2	48	50
Total	10	90	100

$$\chi_p^2 = 4.00 \quad (p = 0.046)$$

$$\chi^2_{MH} = 3.96 \quad (p = 0.047)$$

Note: the Pearson χ^2 test applies to the case where the row margins are fixed but not the column margins, as a test of equivalence between the proportions with events in the two groups. In that case, the variance is slightly different than for the MH test:

$$\mathbf{Var}(d_0) = \frac{n_0 n_1 d(n-d)}{n^3}$$

Now suppose we have K (2×2) tables, all independent, and we want to test for a common group effect $H_0: \psi_j = \psi = 1$ versus $H_A: \psi \neq 1$. The Cochran-Mantel-Haenszel test for a common odds ratio not equal to 1 can be written as:

$$\chi_{CMH}^2 = \frac{\left[\sum_{j=1}^K (D_{0j} - n_{0j} * d_j/n_j)\right]^2}{\sum_{j=1}^K n_{1j} n_{0j} d_j (n_j - d_j) / [n_j^2 (n_j - 1)]}$$

and this statistic is distributed approximately as χ_1^2 . The subscript j refers to the j-th table:

Group	Yes	No	Total
0	d_{0j}	$n_{0j} - d_{0j}$	n_{0j}
1	d_{1j}	$n_{1j} - d_{1j}$	n_{1j}
Total	d_{j}	$n_j - d_j$	n_{j}

How does this apply in survival analysis?

Suppose we observe

Group 1:
$$(X_{11}, \delta_{11}) \dots (X_{1n_1}, \delta_{1n_1})$$

Group 0:
$$(X_{01}, \delta_{01}) \dots (X_{0n_0}, \delta_{0n_0})$$

We could just count the numbers of failures in one of the groups: eg., $D_0 = \sum_{j=1}^K \delta_{0j}$

Example: Leukemia data, just counting up the number of remissions in each treatment group.

Group	Yes	No	Total
0	21	0	21
1	9	12	21
Total	30	12	42

$$\chi_p^2 = 16.8 \quad (p = 0.001)$$
 $\chi_{MH}^2 = 16.4 \quad (p = 0.001)$

But, this does not account for the time at risk.

Conceptually, we would like to compare the KM survival curves. To do this, we first compare hazards at each failure time, and then aggregate over all the failure times.

3.3. TWO SAMPLE TESTS FOR COMPARING SURVIVAL

Cox & Oakes Table 1.1 Leukemia example

Ordered		roup	0		roup	1
Death Times	$\overline{d_j}$	c_j	r_{j}	d_{j}	c_j	r_j
1	2	0	21	0	0	21
2	2	0	19	0	0	21
3	1	0	17	0	0	21
4	2	0	16	0	0	21
5	2	0	14	0	0	21
6	0	0	12	3	1	21
7	0	0	12	1	0	17
8	4	0	12	0	0	16
9	0	0	8	0	1	16
10	0	0	8	1	1	15
11	2	0	8	0	1	13
12	2	0	6	0	0	12
13	0	0	4	1	0	12
15	1	0	4	0	0	11
16	0	0	3	1	0	11
17	1	0	3	0	1	10
19	0	0	2	0	1	9
20	0	0	2	0	1	8
${\bf 22}$	1	0	2	1	0	7
23	1	0	1	1	0	6
25	0	0	0	0	1	5

Logrank Test: Formal Definition

The logrank test can be obtained by constructing a (2×2) table at each distinct death time, and comparing the death rates between the two groups, conditional on the number at risk in the groups. The tables are then combined using the Cochran-Mantel-Haenszel test.

Let $t_1, ..., t_K$ represent the K ordered, distinct death times. At the j-th death time, we have the following table:

Die/Fail							
Group	Yes	No	Total				
0	d_{0j}	$r_{0j} - d_{0j}$	r_{0j}				
1	d_{1j}	$r_{1j} - d_{1j}$	r_{1j}				
Total	d_{j}	$r_j - d_j$	r_j				

where d_{0j} and d_{1j} are the number of deaths in group 0 and 1, respectively at the j-th death time, and r_{0j} and r_{1j} are the number at risk at that time, in groups 0 and 1.

The logrank test is:

$$\chi_{logrank}^{2} = \frac{\left[\sum_{j=1}^{K} (D_{0j} - r_{0j} * d_{j}/r_{j})\right]^{2}}{\sum_{j=1}^{K} \frac{r_{1j}r_{0j}d_{j}(r_{j}-d_{j})}{[r_{j}^{2}(r_{j}-1)]}}$$

Assuming the tables are all independent, then this statistic will have an approximate χ^2 distribution with 1 df.

Based on the motivation for the logrank test, which of the survivalrelated quantities are we comparing at each time point?

- $\sum_{j=1}^{K} w_j \left[\hat{S}_1(t_j) \hat{S}_2(t_j) \right]$?
- $\sum_{j=1}^{K} w_j \left[\hat{\lambda}_1(t_j) \hat{\lambda}_2(t_j) \right]$?
- $\sum_{j=1}^{K} w_j \left[\hat{\Lambda}_1(t_j) \hat{\Lambda}_2(t_j) \right]$?

First several tables of leukemia data

CMH analysis of leukemia data

TABLE 1 OF TRTMT BY REMISS CONTROLLING FOR FAILTIME=1

TABLE 3 OF TRTMT BY REMISS CONTROLLING FOR FAILTIME=3

TRTMT REMISS TRTMT REMISS

Frequence	d	01	1	Total
(0	20	2 1	21
	1 	21 20	0 1	21
Total	•	40	2	42

Frequence	•	0	_	•	Total
(16 16.553	1	İ	17
		21 20.447	0 0.5526	 	21
Total	+	+ 37	1	+	38

TABLE 2 OF TRTMT BY REMISS CONTROLLING FOR FAILTIME=2

TABLE 4 OF TRTMT BY REMISS CONTROLLING FOR FAILTIME=4

TRTMT	REMISS			TRTMT	REMISS		
Frequency Expected			Total	Frequency Expected	0	•	Total
0	17	2 0.95	19	0	14 15.135	2 0.8649	16
1	21	0 1.05	21	1	21 19.865	0 1.1351	21
Total	38	2	40	Total	35	2	37

3.3. TWO SAMPLE TESTS FOR COMPARING SURVIVAL

$\mathbf{Ordered}$	Gro	up 0	Com	bined			
Death Times	d_{0j}	r_{0j}	d_{j}	r_j	e_{j}	$o_j - e_j$	v_{j}
1	2	21	2	42	1.00	1.00	0.488
2	2	19	2	40	0.95	1.05	
3	1	17	1	38	0.45	0.55	
4	2	16	2	37	0.86	1.14	
5	2	14	2	35			
6	0	12	3	33			
7	0	12	1	29			
8	4	12	4	28			
10	0	8	1	23			
11	2	8	2	21			
12	2	6	2	18			
13	0	4	1	16			
15	1	4	1	15			
16	0	3	1	14			
17	1	3	1	13			
22	1	2	2	9			
23	1	1	2	7			
Sum						10.251	6.257

Calculating the logrank statistic by hand Leukemia Example:

$$o_{j} = d_{0j}$$

 $e_{j} = d_{j}r_{0j}/r_{j}$
 $v_{j} = r_{1j}r_{0j}d_{j}(r_{j} - d_{j})/[r_{j}^{2}(r_{j} - 1)]$
 $\sum_{j}(o_{j} - e_{j}) = 10.251$
 $\sum_{j}v_{j} = 6.257$

$$\chi_{logrank}^2 = \frac{\left(\sum_j (o_j - e_j)\right)^2}{\sum_j v_j} = \frac{(10.251)^2}{6.257} = 16.793$$

Notes about logrank tests:

- The logrank statistic depends on ranks of event times only, eg, on the order in which events and censorings occur.
- If there are no tied deaths, then $d_j = 1$ and the logrank has the simplified form:

$$\frac{\left[\sum_{j=1}^{K} (d_{0j} - \frac{r_{0j}}{r_j})\right]^2}{\sum_{j=1}^{K} r_{1j} r_{0j} / r_j^2}$$

- Numerator can be interpreted as $\sum (o e)$ where "o" is the observed number of deaths in group 0, and "e" is the expected number, given the risk sets. The expected number equals #deaths × proportion in group 0 at risk.
- The (o e) terms in the numerator can be written as

$$\frac{r_{0j}r_{1j}}{r_j}(\hat{\lambda}_{1j}-\hat{\lambda}_{0j})$$

• It does not matter which group you choose to sum over.

To see this, note that if we summed up (o-e) over the death times for the 6MP group we would get -10.251, and the sum of the variances is the same. So when we square the numerator, the test statistic is the same.

Power

Analogous to the CMH test for a series of tables at different levels of a confounder, the logrank test is most powerful when "odds ratios" are constant over time intervals. That is, it is most powerful for proportional hazards.

Checking the assumption of proportional hazards:

- check to see if the estimated survival curves cross if they do, then this is evidence that the hazards are <u>not</u> proportional
- more formal test: any ideas? We will come back to this later.

What should be done if the hazards are NOT proportional?

- If the difference between hazards has a consistent sign, the logrank test usually performs well.
- Other tests are available that are more powerful against different alternatives, e.g. weighted logrank tests, parametric tests, the Kolmogorov-Smirnoff non-parametric test.

Getting the logrank statistic using SAS

- We still use PROC LIFETEST
- Add a "STRATA" command, with treatment or exposure variable
- By default, the chi-square test is provided (2-sided)
- However, it also gives you the terms you need to calculate the 1-sided test; this is useful if we want to know which of the two groups has the higher estimated hazard over time.
- The STRATA command also gives the Gehan-Wilcoxon test (which we will talk about next)

```
Title 'Cox and Oakes example';
data leukemia;
    input weeks remiss trtmt;
    cards;
      0
            1
6
      1
      1
                     /* data for 6MP group */
      1
            1
9
      0
            1
etc
            0
      1
                     /* data for placebo group */
            0
      1
            0
2
      1
            0
etc
proc lifetest data=leukemia;
 time weeks*remiss(0);
  strata trtmt;
 title 'Logrank test for leukemia data';
run;
```

3.3. TWO SAMPLE TESTS FOR COMPARING SURVIVAL

Logrank test for leukemia data

Summary of the Number of Censored and Uncensored Values

TRTMT	Total	Failed	Censored	%Censored
6-MP Control	21 21	9 21	12 0	57.1429 0.0000
Total	42	30	12	28.5714

Testing Homogeneity of Survival Curves over Strata Time Variable ${\tt FAILTIME}$

Rank Statistics

TRTMT	Log-Rank	Wilcoxon
6-MP	-10.251	-271.00
Control	10.251	271.00

Covariance Matrix for the Log-Rank Statistics

TRTMT	6-MP	Control		
6-MP	6.25696	-6.25696		
Control	-6.25696	6.25696		

Test of Equality over Strata

	- •		Pr >	
Test	Chi-Square	DF	Chi-Square	
	•		•	
Log-Rank	16.7929	1	0.0001	<pre><== Here's the one we want!!</pre>
Wilcoxon	13.4579	1	0.0002	
-2Log(LR)	16.4852	1	0.0001	

Getting the Logrank test in Stata

Example using leukemia data (already saved as Stata dataset leukem.dat):

- . use leukem
- . stset remiss status
- . sts test trt

failure _d: status
analysis time _t: remiss

Log-rank test for equality of survivor functions

 trt	Events observed	Events expected
0 1	21 9	10.75 19.25
Total	30	30.00
	chi2(1) = Pr>chi2 =	16.79 0.0000

[Note: interpret Pr>chi2=0.0000 to mean p<0.0001]

3.3.2 Linear Rank Tests

Linear rank tests are generalizations of the logrank test.

The logrank and other tests can be derived by assigning scores to the ranks of the death times, and are members of a general class of linear rank tests (for more detail, see Lee, ch 5)

First, define

$$\hat{\Lambda}(t) = \sum_{j: t_j \le t} \frac{d_j}{r_j}$$

where d_j and r_j are the number of deaths and the number at risk, respectively at the j-th ordered death time.

Then assign these scores (suggested by Peto and Peto):

EVENT	Score
Death at t_j	$w_j = 1 - \hat{\Lambda}(t_j)$
Censoring at t_j	$w_j = -\hat{\Lambda}(t_j)$

To calculate the logrank test, simply sum up the scores for group 0.

Example Group 0: 15, 18, 19, 19, 20

Group 1: 16+, 18+, 20+, 23, 24+

Calculation of logrank as a linear rank statistic

ediculation of logitalik as a linear rank statis					
Ordered Data	Group	d_{j}	r_{j}	$\hat{\Lambda}(t_j)$	score w_j
15	0	1	10	0.100	0.900
16 ⁺	1	0	9	0.100	-0.100
18	0	1	8	0.225	0.775
18 ⁺	1	0	7	0.225	-0.225
19	0	2	6	0.558	0.442
20	0	1	4	0.808	0.192
20^{+}	1	0	3	0.808	-0.808
23	1	1	2	1.308	-0.308
24+	1	0	1	1.308	-1.308

The logrank statistic S is sum of scores for group 0:

$$S = 0.900 + 0.775 + 0.442 + 0.442 + 0.192 = 2.75$$

3.3. TWO SAMPLE TESTS FOR COMPARING SURVIVAL

Estimated variance of the logrank test

$$Var(S) = \frac{n_0 n_1 \sum_{j=1}^{n} w_j^2}{n(n-1)}$$

In this case, Var(S) = 1.210, so

$$Z = \frac{2.75}{\sqrt{1.210}} = 2.50 \implies \chi^2_{logrank} = (2.50)^2 = 6.25$$

Why is this form of the logrank equivalent?

The logrank statistic S is equivalent to $\sum (o - e)$ over the distinct death times, where "o" is the observed number of deaths in group 0, and "e" is the expected number, given the risk sets.

At deaths: weights are $1 - \hat{\Lambda}$

At censorings: weights are $-\hat{\Lambda}$

So we are summing up "1's" for deaths (to get d_{0j}), and subtracting $-\hat{\Lambda}$ at both deaths and censorings. This amounts to subtracting d_j/r_j at each death or censoring time in group 0, at or after the *j*-th death. Since there are a total of r_{0j} of these, we get $e = r_{0j} * d_j/r_j$.

Why is it called the logrank test?

Since $S(t) = \exp(-\Lambda(t))$, an alternative estimator of S(t) is:

$$\hat{S}(t) = \exp(-\hat{\Lambda}(t)) = \exp(-\sum_{j:t_j < t} \frac{d_j}{r_j})$$

So, we can think of $\hat{\Lambda}(t) = -\log(\hat{S}(t))$ as yielding the "log-survival" scores used to calculate the statistic.

3.3. TWO SAMPLE TESTS FOR COMPARING SURVIVAL

3.3.3 CMH-type Logrank versus the "Linear Rank" Logrank

A. CMH-type Logrank:

We motivated the logrank test through the CMH statistic for testing $H_o: OR = 1$ over K tables, where K is the number of distinct death times. This turned out to be what we get when we use the "STRATA" statement in SAS.

B. Linear Rank logrank:

The linear rank version of the logrank test is based on adding up "scores" for one of the two treatment groups. The particular scores that gave us the same logrank statistic were based on the Nelson-Aalen estimator, i.e., $\hat{\Lambda} = \sum \hat{\lambda}(t_j)$. This is what you get when you use the "TEST" statement in SAS.

Here are some comparisons, with a new example to show when the two types of logrank statistics will be equal.

First, let's consider an example from Chapter 5 of Lee:


Ten female patients with breast cancer are randomized to receive either CMF (cyclic administration of cyclophosphamide, methatraxate, and fluorouracil) or no treatment after a radical mastectomy. At the end of two years these times to relapse have been recorded in months.

Example Group 0: 15, 18, 19, 19, 20

Group 1: 16+, 18+, 20+, 23, 24+

The Kaplan-Meier curves are shown next.

Logrank test for Lee: breast cancer data



A. The CMH-type logrank statistic: (using the STRATA statement)

Rank Statistics

TRTMT	Log-Rank	Wilcoxon
Control	2.7500	18.000
Treated	-2.7500	-18.000

Covariance Matrix for the Log-Rank Statistics

TRTMT	Control	Treated
Control	1.08750	-1.08750
Treated	-1.08750	1.08750

Test of Equality over Strata

		Pr >		
Chi-Square	DF	Chi-Square		
6.9540	1	0.0084		
5.5479	1	0.0185		
3.3444	1	0.0674		
	6.9540 5.5479	6.9540 1 5.5479 1		

This is exactly the same chi-square test that you would get if you calculated the numerator of the logrank as $\sum (o_j - e_j)$ and the individual variance terms at each failure time as $v_j = r_{1j}r_{0j}d_j(r_j - d_j)/[r_j^2(r_j - 1)]$

Ordered	Gro	up 0	Combined				
Death Times	d_{0j}	r_{0j}	d_{j}	r_j	e_{j}	$o_j - e_j$	v_{j}
15	1	5	1	10	0.50	0.50	0.2500
18	1	4	1	8	0.50	0.50	0.2500
19	2	3	2	6	1.00	1.00	0.4000
20	1	1	2	4	0.25	0.75	0.1870
23	0	0	1	2	0.00	0.00	0.0000
Sum						2.75	1.0875

$$\chi^2_{logrank} = \frac{(2.75)^2}{1.0875} = 6.954$$

B. The "linear rank" logrank statistic: (using the TEST statement)

Univariate Chi-Squares for the LOG RANK Test

Variable	Test Statistic	Standard Deviation	Chi-Square	Pr > Chi-Square
GROUP	2.7500	1.0897	6.3684	0.0116

Covariance Matrix for the LOG RANK Statistics

Variable TRTMT

TRTMT 1.18750

The test statistic is exactly the same for the linear rank and the CMH logrank tests, but the standard deviation is slightly different.

This is actually very close to what we would get if we use the Nelson-Aalen based "scores":

Calculation of	of logran	k as a	linear	rank s	statistic
Ordered Data	Group	d_{j}	r_{j}	$\hat{\Lambda}(t_j)$	score w_j
15	0	1	10	0.100	0.900
16 ⁺	1	0	9	0.100	-0.100
18	0	1	8	0.225	0.775
18 ⁺	1	0	7	0.225	-0.225
19	0	2	6	0.558	0.442
20	0	1	4	0.808	0.192
20^{+}	1	0	3	0.808	-0.808
23	1	1	2	1.308	-0.308
24^{+}	1	1	1	1.308	-1.308
$\overline{\text{Sum}(\text{grp }0)}$					2.750

Note that the numerator is the exact same number (2.75) in both versions of the logrank test. The difference in the denominator is due to the way that ties are handled.

CMH-type variance:

$$var = \sum \frac{r_{1j}r_{0j}d_j(r_j - d_j)}{r_j^2(r_j - 1)}$$
$$= \sum \frac{r_{1j}r_{0j}}{r_j(r_j - 1)} \frac{d_j(r_j - d_j)}{r_j}$$

Linear rank type variance:

$$var = \frac{n_0 n_1 \sum_{j=1}^{n} w_j^2}{n(n-1)}$$

An example where there are no tied death times

Example I Group 0: 15, 18, 19, 21, 22

Group 1: 16+, 17+, 20+, 23, 24+

A. The CMH-type logrank statistic:

(using the STRATA statement)

Rank Statistics

TRTMT	Log-Rank	Wilcoxor
Control	2.5952	15.000
Treated	-2.5952	-15.000

Covariance Matrix for the Log-Rank Statistics

TRTMT	Control	Treated
Control	1.21712	-1.21712
Treated	-1.21712	1.21712

Test of Equality over Strata

			Pr >
Test	Chi-Square	DF	Chi-Square
Log-Rank	5.5338	1	0.0187
Wilcoxon	4.3269	1	0.0375
-2Log(LR)	3.1202	1	0.0773

B. The "linear rank" logrank statistic: (using the TEST statement)

Univariate Chi-Squares for the LOG RANK Test

Variable	Test Statistic	Standard Deviation	Chi-Square	Pr > Chi-Square
TRTMT	2.5952	1.1032	5.5338	0.0187

Covariance Matrix for the LOG RANK Statistics

Variable TRTMT

TRTMT 1.21712

Note that this time, the variances of the two logrank statistics are exactly the same, equal to 1.217.

If there are no tied event times, then the two versions of the test will yield identical results. The more ties we have, the more it matters which version we use.

3.3.4 'Wilcoxon' tests

Gehan's Generalized Wilcoxon Test

First, let's review the Wilcoxon test for uncensored data: Denote observations from two samples by:

$$(X_1, X_2, \dots, X_m)$$
 and (Y_1, Y_2, \dots, Y_n)

Order the combined sample and define:

$$Z_{(1)} < Z_{(2)} < \cdots < Z_{(m+n)}$$
 $R_{i1} = \mathbf{rank of } X_i$
 $R_1 = \sum_{i=1}^{m+n} R_{i1}$

Reject H_0 if R_1 is too big or too small, according to

$$\frac{R_1 - E(R_1)}{\sqrt{Var(R_1)}} \sim N(0, 1)$$

where

$$E(R_1) = \frac{m(m+n+1)}{2}$$
 $Var(R_1) = \frac{mn(m+n+1)}{12}$

The Mann-Whitney form of the Wilcoxon is defined as:

$$U(X_i, Y_j) = U_{ij} = \begin{cases} +1 & \text{if} \quad X_i > Y_j \\ 0 & \text{if} \quad X_i = Y_j \\ -1 & \text{if} \quad X_i < Y_j \end{cases}$$

and

$$U = \sum_{i=1}^{n} \sum_{j=1}^{m} U_{ij}.$$

There is a simple correspondence between U and R_1 :

$$R_1 = m(m+n+1)/2 + U/2$$

so
$$U = 2R_1 - m(m+n+1)$$

Therefore,

$$E(U) = 0$$

$$Var(U) = mn(m+n+1)/3$$

Extending Wilcoxon to censored data

The Mann-Whitney form leads to a generalization for censored data. Define

$$U(X_i, Y_j) = U_{ij} = \begin{cases} +1 & \text{if} & x_i > y_j \text{ or } x_i^+ \ge y_j \\ 0 & \text{if} & x_i = y_i \text{ or lower value censored} \\ -1 & \text{if} & x_i < y_j \text{ or } x_i \le y_j^+ \end{cases}$$

Then define

$$W = \sum_{i=1}^{n} \sum_{j=1}^{m} U_{ij}$$

Thus, there is a contribution to W for every comparison where both observations are failures (except for ties), or where a censored observation is greater than or equal to a failure.

Looking at all possible pairs of individuals between the two treatment groups makes this a nightmare to compute by hand!

Gehan found an easier way to compute the above. First, pool the sample of (n+m) observations into a single group, then compare each individual with the remaining n+m-1: For comparing the *i*-th individual with the *j*-th, define

$$U_{ij} = \begin{cases} +1 & \text{if} & t_i > t_j \text{ or } t_i^+ \ge t_j \\ -1 & \text{if} & t_i < t_j \text{ or } t_i \le t_j^+ \\ 0 & otherwise \end{cases}$$

Then

$$U_i = \sum_{j=1}^{m+n} U_{ij}$$

Thus, for the *i*-th individual, U_i is the number of observations which are definitely less than t_i minus the number of observations that are definitely greater than t_i . We assume censorings occur after deaths, so that if $t_i = 18^+$ and $t_j = 18$, then we add 1 to U_i .

3.3. TWO SAMPLE TESTS FOR COMPARING SURVIVAL

The Gehan statistic is defined as

$$U = \sum_{i=1}^{m+n} U_i \mathbf{1}_{\{i \text{ in group } \mathbf{0}\}}$$
$$= W$$

U has mean 0 and variance

$$var(U) = \frac{mn}{(m+n)(m+n-1)} \sum_{i=1}^{m+n} U_i^2$$

Example from Lee:

Group 0: 15, 18, 19, 19, 20

Group 1: 16+, 18+, 20+, 23, 24+

Time	Group	U_i	U_i^2
15	0	-9	81
16^+	1	1	1
18	0	-6	36
18^+	1	2	4
19	0	-2	4
19	0	-2	4
20	0	1	1
20^{+}	1	5	25
23	1	4	16
24^{+}	1	6	36
SUM		-18	208

Using these calculations we have:

$$U = -18$$

$$Var(U) = \frac{(5)(5)(208)}{(10)(9)}$$

$$= 57.78$$

and
$$\chi^2 = (-18)^2/57.78 = 5.61$$

Obtaining the Gehan-Wilcoxon test in SAS

```
data leedata;
  infile 'lee.dat';
  input time cens group;
proc lifetest data=leedata;
 time time*cens(0);
  strata group; run;
```

SAS OUTPUT: Gehans Wilcoxon test

```
Rank Statistics
```

2.7500 -2.7500	18.000 -18.000

Covariance Matrix for the Wilcoxon Statistics

TRTMT	Control	Treated
Control	58.4000	-58.4000
Treated	-58.4000	58.4000

Test of E	quality over	Strata	a				
			Pr >				
Test	Chi-Square	DF	Chi-Square				
Log-Rank	6.9540	1	0.0084				
Wilcoxon	5.5479	1	0.0185	**this	is	Gehan's	test
-2Log(LR)	3.3444	1	0.0674				

Notes about SAS Wilcoxon Test:

SAS calculates the Wilcoxon as -U instead of U (sign = logrank sign). Also, SAS gets something slightly different for the variance, and this does not seem to depend on whether there are ties. E.g., the hypothetical dataset on p.6 without ties yields U = -15 and $\sum U_i^2 = 182$:

$$Var(U) = \frac{(5)(5)(182)}{(10)(9)} = 50.56$$
 and $\chi^2 = \frac{(-15)^2}{50.56} = 4.45$

while SAS gives the following:

Rank Statistics

TRTMT	Log-Rank	Wilcoxon
Control	2.5952	15.000
Treated	-2.5952	-15.000

Covariance Matrix for the Wilcoxon Statistics

TRTMT	Control	Treated
Control	52.0000	-52.0000
Treated	-52.0000	52.0000

Test of Equality over Strata

			Pr >
Test	Chi-Square	DF	Chi-Square
Log-Rank	5.5338	1	0.0187
Wilcoxon	4.3269	1	0.0375
-2Log(LR)	3.1202	1	0.0773

Why aren't they exactly the same?

There may be very slight differences in computational formulas that seem to make a difference for this example.

However, these examples only include 5 subjects per treatment arm.

In practice, we should not be applying a logrank test to such a small dataset! (we've used it here only to show computations)

Even though the test is non-parametric in terms of not making distributional assumptions, it still relies on a large enough sample size for the test statistics to be appropriate (the test statistics are "asymptotic" or "large sample" tests).

With larger sample sizes, the computational differences become negligible.

3.3. TWO SAMPLE TESTS FOR COMPARING SURVIVAL

Obtaining the Gehan-Wilcoxon test in Stata

(same as before, but adding "Wilcoxon" option to test command)

Example: (leukemia data)

- . stset remiss status
- . sts test trt, wilcoxon

Wilcoxon (Breslow) test for equality of survivor functions

trt	Events observed	expected	Sum of ranks
0	21 9	10.75 19.25	271 -271
Total	30	30.00	0
	chi2(1) = Pr>chi2 =	13.46 0.0002	

This is equivalent to the Gehan Wilcoxon test provided by SAS (p.27).

3.3.5 Generalized Wilcoxon: Peto & Peto, Prentice

For a death at t: Score = $\hat{S}(t+) + \hat{S}(t-) - 1$

For a censoring at t: Score = $\hat{S}(t+) - 1$

The test statistic is $\sum (scores)$ for group 0.


Time	Group	d_{j}	r_{j}	$\hat{S}(t+)$	score w_j
15	0	1	10	0.900	0.900
16^{+}	1	0	9	0.900	-0.100
18	0	1	8	0.788	0.688
18 ⁺	1	0	7	0.788	-0.212
19	0	2	6	0.525	0.313
20	0	1	4	0.394	-0.081
20^{+}	1	0	3	0.394	-0.606
23	1	1	2	0.197	-0.409
24+	1	0	1	0.197	-0.803

$$\sum w_j \, \mathbf{1}_{\{j \text{ in group } \mathbf{0}\}} = 0.900 + 0.688 + 2 * (0.313) + (-0.081) = 2.13$$

$$Var(S) = \frac{n_0 n_1 \sum_{j=1}^n w_j^2}{n(n-1)} = 0.765$$

$$\mathbf{so} \quad Z = 2.13 / \sqrt{0.765} = 2.433$$

Chemo compared with bone marrow transplantation, NEJM'98



On page 1649

Gage cure-rate model.²⁶ Accrual and follow-up goals were set to provide the study with at least 80 percent power to detect a 50 percent increase in the cure rate and a 50 percent increase in median disease-free survival among the patients destined to relapse, with the use of a generalized Wilcoxon 5 percent two-sided test.²⁷ The study design called for a total of approximately 130 patients randomly assigned to each of the two therapies — autologous marrow transplantation and high-dose cytarabine — with 180 relapses expected in order to achieve the desired power. The protocol pro-

For time-to-event comparisons for outcomes other than the main end point, the log-rank statistic was used for purposes of comparability with the literature. In survival and disease-free survival curves, all patients who were eligible for initial study entry who had a documented complete remission were analyzed on an intention-to-treat basis, according to the treatment assigned after remission, regardless of whether they received the intended therapy. Survival and disease-free survival curves were estimated by the method of Kaplan and Meier. The independence of row and column effects in contingency tables was tested with either Fisher's exact test or exact methods for ordered categorical data. The independence of the column of the column of the contingency tables was tested with either Fisher's exact test or exact methods for ordered categorical data.

From the abstract

Results In an intention-to-treat analysis, we found no significant differences in disease-free survival among patients receiving high-dose chemotherapy, those undergoing autologous bone marrow transplantation, and those undergoing allogeneic marrow transplantation. The median follow-up was four years. Survival after complete remission was somewhat better after chemotherapy than after autologous marrow transplantation (P=0.05). There was a marginal advantage in terms of overall survival with chemotherapy as compared with allogeneic marrow transplantation (P=0.04).

On page 1652

for high-dose cytarabine. The times to marrow transplantation were significantly longer than the times to chemotherapy (P=0.001), regardless of whether the

3.3.6 The Tarone-Ware class of tests

This general class of tests is like the logrank test, but adds weights w_j . The logrank test, Wilcoxon test, and Peto-Prentice Wilcoxon are included as special cases.

$$\chi_{tw}^{2} = \frac{\left[\sum_{j=1}^{K} \frac{w_{j}(d_{1j} - r_{1j} * d_{j}/r_{j})\right]^{2}}{\sum_{l=1}^{K} \frac{w_{j}^{2} r_{1j} r_{0j} d_{j}(r_{j} - d_{j})}{r_{j}^{2}(r_{j} - 1)}}$$

Test	Weight w_j
Logrank	$w_j = 1$
Gehan's Wilcoxon	$w_j = r_j$
Peto/Prentice	$w_j = n\widehat{S}(t_j)$
Fleming-Harrington	$w_j = [\hat{S}(t_j)]^p [1 - \hat{S}(t_j)]^q$
Tarone-Ware	$w_j = \sqrt{r_j}$

Note: these weights w_j are not the same as the scores w_j we've been talking about earlier, and they apply to the CMH-type form of the test statistic rather than $\sum(scores)$ over a single treatment group.

More details on the Fleming-Harrington test:


The parameters p and q can be any non-negative numbers:

- If p and q are both equal to 0, then $w_j = 1$ and we get the usual logrank test
- If p = 1 and q = 0, then the test is similar to the Peto-Prentice test (this is the default "Fleming" test in SAS PROC LIFETEST)
- If q = 1 and p = 0, what happens to w_j over follow-up time?
- If p and q are both equal to 1, the weight w_j reaches a maximum at the median, and is smaller for both large and small t_j .

Back to our example: Time to relapse of leukemia patients

Based on the Tarone-Ware class of tests, which weights might yield the most powerful test?

Figure 3.1: Kaplan-Meier curves for both trt groups Leukemia study (Cox and Oakes)



Obtaining Tarone-Ware class of tests in SAS:

In SAS, these two-sample comparisons can be obtained by adding the TEST=ALL option to the STRATA statement.

```
proc lifetest data=leukem outsurv=survdat;
  strata trtmt / test=all;
  time remiss*status(0);
  title 'Logrank test with proc lifetest - strata statement';
  title2 'With Tarone-Ware tests for comparing 2 samples';
run;
```

OUTPUT FROM SAS:

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square
Log-Rank	16.7929	1	<.0001
Wilcoxon	13.4579	1	0.0002
Tarone	15.1236	1	0.0001
Peto	14.0841	1	0.0002
Modified Peto	13.9113	1	0.0002
Fleming(1)	14.4572	1	0.0001

3.3.7 Which test should we use?

CMH-type or Linear Rank?

If there are not a high proportion of ties, then it doesn't really matter since:

- The two Wilcoxons are similar to each other
- The two logrank tests are similar to each other

Logrank or Wilcoxon?

- Both tests have the right Type I level for testing the null hypothesis of equal survival, $H_o: S_1(t) = S_2(t)$
- The choice of which test may therefore depend on the alternative hypothesis, which will drive the power of the test.

• The Wilcoxon is sensitive to early differences between survival, while the logrank is sensitive to later ones. This can be seen by the relative weights they assign to the test statistic:

LOGRANK
$$numerator = \sum_{j} (o_j - e_j)$$
WILCOXON $numerator = \sum_{j} r_j (o_j - e_j)$

• The logrank is most powerful under the assumption of proportional hazards:

$$\frac{\lambda_1(t)}{\lambda_2(t)} = \theta$$

which implies an alternative in terms of the survival functions of H_a : $S_1(t) = [S_2(t)]^{\theta}$

- The Wilcoxon has high power when the failure times are lognormally distributed, with equal variance in both groups but a different mean. It will turn out that this is the assumption of an accelerated failure time model.
- Both tests will lack power if the survival curves (or hazards) "cross". However, that does not necessarily make them *invalid*...

Comparison between TEST and STRATA in SAS for 2 examples:

Data from Lee (n=10):

from STRATA:

Test of Equality over Strata

Test	Chi-Square	DF	Pr > Chi-Square				
Log-Rank	6.9540	1	0.0084				
Wilcoxon	5.5479	1	0.0185	**this	is	Gehan's	test
-2Log(LR)	3.3444	1	0.0674				

from TEST:

Univariate Chi-Squares for the WILCOXON Test

	Test	Standard		Pr >
Variable	Statistic	Deviation	Chi-Square	Chi-Square
GROUP	1.8975	0.7508	6.3882	0.0115

Univariate Chi-Squares for the LOG RANK Test

Variable	Test Statistic	Standard Deviation	Chi-Square	Pr > Chi-Square
GROUP	2.7500	1.0897	6.3684	0.0116

Previous example with leukemia data:

from STRATA:

Test of Equality over Strata

			Pr >
Test	Chi-Square	DF	Chi-Square
	4.0 7000		0.0004
Log-Rank	16.7929	1	0.0001
Wilcoxon	13.4579	1	0.0002
-2Log(LR)	16.4852	1	0.0001

from TEST:

Univariate Chi-Squares for the WILCOXON Test

Variable	Test Statistic	Standard Deviation	Chi-Square	Pr > Chi-Square
GROUP	6.6928	1.7874	14.0216	0.0002
Univariate	Chi-Squares	for the LOG	RANK Test	
Variable	Test Statistic	Standard Deviation	Chi-Square	Pr > Chi-Square
GROUP	10.2505	2.5682	15.9305	0.0001

3.4 P-sample and stratified logrank tests

We have been discussing two sample problems. In practice, more complex settings often arise:

• There are more than two treatments or groups, and the question of interest is whether the groups differ from each other:

$$H_0: S_1(t) = S_2(t) = ... = S_P(t)$$
 for all t versus $H_A:$ not $H_0.$

- We are interested in a comparison between two groups, but we wish to adjust for another factor that may confound the analysis
- We want to adjust for lots of covariates.

We will first talk about comparing the survival distributions between more than 2 groups, and then about adjusting for other covariates.

$_{3.4.1}$ P-sample logrank

Suppose we observe data from P different groups, and the data from group p (p = 1, ..., P) are:

$$(X_{p1},\delta_{p1})\dots(X_{pn_p},\delta_{pn_p})$$

We now construct a $(P \times 2)$ table at each of the K distinct death times, and compare the death rates between the P groups, conditional on the number at risk. We then combine tables using the CMH approach.

Let t_1,t_K represent the K ordered, distinct death times. At the j-th death time, we have the following table:

Group	Yes	No	Total
1	d_{1j}	$r_{1j} - d_{1j}$	r_{1j}
•	•	•	•
D	.1	1	
${f P}$	d_{Pj}	$r_{Pj} - d_{Pj}$	r_{Pj}
Total	d_i	$r_i - d_i$	r_i

where d_{pj} is the number of deaths in group p at the j-th death time, and r_{pj} is the number at risk at that time.

If we were just focusing on this one table, then a $\chi^2_{(P-1)}$ test statistic could be constructed using "o"s and "e"s, like before.

Example: Toxicity in a clinical trial with 3 treatments

TABLE OF GROUP BY TOXICITY
GROUP TOXICITY

Frequenc	:y		
Row Pct	lno	lyes	Total
	-+	+	-+
1	. 42	2 8	50
	84.00	16.00	1
	-+	+	-+
2	! 48	3 2	50
	96.00	4.00	1
	-+	+	-+
3	38	3 12	50
	76.00	24.00	1
	-+	+	-+
Total	128	3 22	150

STATISTICS FOR TABLE OF GROUP BY TOXICITY

Statistic	DF	Value	Prob
Chi-Square		8.097	0.017
Likelihood Ratio Chi-Square	2	9.196	0.017
Mantel-Haenszel Chi-Square	1	1.270	0.260

Cochran-Mantel-Haenszel Statistics (Based on Table Scores)

Statistic	Alternative Hypothesis	DF	Value	Prob
1	Nonzero Correlation	1	1.270	0.260
2	Row Mean Scores Differ	2	8.043	0.018
3	General Association	2	8.043	0.018

Formal Calculations:

Let $O_j = (d_{1j}, ...d_{(P-1)j})^T$ be a vector of the observed number of failures in groups 1 to (P-1), respectively, at the *j*-th death time. Given the risk set sizes r_{1j} , ... r_{Pj} , and the fact that there are d_j deaths, then O_j has a distribution like a multivariate version of the Hypergeometric. O_j has mean:

$$\mathbf{E}_{j} = (\frac{d_{j} r_{1j}}{r_{j}}, \dots, \frac{d_{j} r_{(P-1)j}}{r_{j}})^{T}$$

and variance covariance matrix:

$$\mathbf{V}_{j} = \begin{pmatrix} v_{11j} & v_{12j} & \dots & v_{1(P-1)j} \\ & v_{22j} & \dots & v_{2(P-1)j} \\ & \dots & & \dots \\ & & v_{(P-1)(P-1)j} \end{pmatrix}$$

where the ℓ -th diagonal element is:

$$v_{\ell\ell j} = r_{\ell j}(r_j - r_{\ell j})d_j(r_j - d_j)/[r_j^2(r_j - 1)]$$

and the ℓm -th off-diagonal element is:

$$v_{\ell mj} = r_{\ell j} r_{mj} d_j (r_j - d_j) / [r_j^2 (r_j - 1)]$$

The resulting χ^2 test for a single $(P \times 1)$ table would have (P-1) degrees and is constructed as follows:

$$(\mathbf{O}_j - \mathbf{E}_j)^T \mathbf{V}_j^{-1} (\mathbf{O}_j - \mathbf{E}_j)$$

Generalizing to K tables

Analogous to what we did for the two sample logrank, we replace the O_j , E_j and V_j with the sums over the K distinct death times. That is, let $O = \sum_{j=1}^k O_j$, $E = \sum_{j=1}^k E_j$, and $V = \sum_{j=1}^k V_j$. Then, the test statistic is:

$$(\mathbf{O} - \mathbf{E})^T \mathbf{V}^{-1} (\mathbf{O} - \mathbf{E})$$

Example:

Time taken to finish a test with 3 different noise distractions. All tests were stopped after 12 minutes.

	Noise Level				
Group	Group	Group			
1	2	3			
9.0	10.0	12.0			
9.5	12.0	${\bf 12}^+$			
9.0	${\bf 12}^+$	${\bf 12}^+$			
8.5	11.0	${\bf 12}^+$			
10.0	12.0	${\bf 12}^+$			
10.5	10.5	${\bf 12}^+$			

Let's start the calculations ...

Observed data table:

Ordered	Gro	up 1	Gro	up 2	Gro	up 3	Com	bined
Times	d_{1j}	r_{1j}	d_{2j}	r_{2j}	d_{3j}	r_{3j}	d_j	r_{j}
8.5	1	6	0	6	0	6		
9.0	2	5	0	6	0	6		
9.5	1	3	0	6	0	6		
10.0	1	2	1	6	0	6		
10.5	1	1	1	5	0	6		
11.0	0	0	1	4	0	6		
12.0	0	0	2	3	1	6		

Expected table:

Ordered	Gro	up 1	Gro	up 2	Gro	up 3	Com	bined
Times	o_{1j}	e_{1j}	o_{2j}	e_{2j}	o_{3j}	e_{3j}	o_j	e_{j}
8.5								
9.0								
9.5								
10.0								
10.5								
11.0								
12.0								

Doing the P-sample test by hand is cumbersome ...

3.4. P-SAMPLE AND STRATIFIED LOGRANK TESTS

SAS program for *P*-sample logrank

```
Title 'Testing with noise example';
data noise;
   input testtime finish group;
   cards;
        1
             1
9
9.5
             1
9.0
             1
8.5
10
10.5
             1
10.0
12
12
11
12
10.5
             3
12
12
12
             3
12
12
             3;
12
proc lifetest data=noise;
  time testtime*finish(0);
  strata group; run;
```

Testing Homogeneity of Survival Curves over Strata

Time Variable TESTTIME

Rank Statistics

GROUP	Log-Rank	Wilcoxon
1	4.4261	68.000
2	0.4703	-5.000
3	-4.8964	-63.000

Covariance Matrix for the Log-Rank Statistics

GROUP	1	2	3
1	1.13644	-0.56191	-0.57454
2	-0.56191	2.52446	-1.96255
3	-0.57454	-1.96255	2.53709

Covariance Matrix for the Wilcoxon Statistics

GROUP	1	2	3
1	284.808	-141.495	-143.313
2	-141.495	466.502	-325.007
3	-143.313	-325.007	468.320

Test of Equality over Strata

			Pr >
Test	Chi-Square	DF	Chi-Square
Log-Rank	20.3844	2	0.0001
Wilcoxon	18.3265	2	0.0001
-2Log(LR)	5.5470	2	0.0624

3.4. P-SAMPLE AND STRATIFIED LOGRANK TESTS

Note: do not use Test in SAS PROC LIFETEST if you want a *P*-sample logrank. Test will interpret the group variable as a measured covariate (i.e., either ordinal or continuous).

In other words, you will get a trend test with only 1 degree of freedom, rather than a P-sample test with (p-1) df. For example:

```
proc lifetest data=noise;
  time testtime*finish(0);
  test group;
run;
```

SAS OUTPUT:

```
Univariate Chi-Squares for the LOG RANK Test
                          Standard
               Test
                                                        Pr >
                                       Chi-Square
                                                     Chi-Square
Variable
            Statistic
                         Deviation
GROUP
               9.3224
                            2.2846
                                         16.6503
                                                       0.0001
Covariance Matrix for the LOG RANK Statistics
Variable
                 GROUP
GROUP
               5.21957
Forward Stepwise Sequence of Chi-Squares for the LOG RANK Test
                                   Pr >
                                             Chi-Square
                                                              Pr >
Variable
             DF
                  Chi-Square
                               Chi-Square
                                              Increment
                                                           Increment
GR.OUP
                    16.6503
                                  0.0001
                                               16.6503
                                                             0.0001
              1
```

3.4.2 The Stratified Logrank

Sometimes, even though we are interested in comparing two groups (or maybe P) groups, we know there are other factors (e.g. center) that also affect the outcome. It would be useful to adjust for these other factors in some way.


Example: For the nursing home data, a logrank test comparing length of stay for those under and over 85 years of age suggests a significant difference (p=0.03).

However, we know that gender has a strong association with length of stay, and also age. Hence, it would be a good idea to STRATIFY the analysis by gender when trying to assess the age effect.

A stratified logrank allows one to efficiently compare groups, when the shapes of the hazards of the different groups differ across strata. It is most efficient when the ratio of the group 1 vs group 2 hazard is constant across strata.

In other words: $\frac{\lambda_{1s}(t)}{\lambda_{2s}(t)} = \theta$ where θ is constant over the strata (s = 1, ..., S).

3.4. P-SAMPLE AND STRATIFIED LOGRANK TESTS



General setup for the stratified logrank

Suppose we want to assess the association between survival and a factor (call this X) that has two different levels. Suppose however, that we want to stratify by a second factor, that has S different levels.

First, divide the data into S separate groups. Within group s (s = 1, ..., S), proceed as though you were constructing the logrank to assess the association between survival and the variable X. That is, let $t_{1s}, ..., t_{K_s s}$ represent the K_s ordered, distinct death times in the s-th group.

At the j-th death time in group s, we have the following table:

Die/Fail			
\mathbf{X}	Yes	No	Total
1	d_{s1j}	$r_{s1j} - d_{s1j}$	r_{s1j}
2	d_{s2j}	$r_{s2j} - d_{s2j}$	r_{s2j}
Total	d_{sj}	$r_{sj} - d_{sj}$	r_{sj}

3.4. P-SAMPLE AND STRATIFIED LOGRANK TESTS

Let O_s be the sum of the "o"s obtained by applying the logrank calculations in the usual way to the data from group s. Similarly, let E_s be the sum of the "e"s, and V_s be the sum of the "v"s.

The stratified logrank is

$$Z = \frac{\sum_{s=1}^{S} (O_s - E_s)}{\sqrt{\sum_{s=1}^{S} (V_s)}}$$

Note how the expected values are caculated based on data from their own strata only

When the statements 'strata' and 'test' are used jointly in the SAS lifetest procedure, then we will get the logrank test for the comparison of the 'test variable' while adjusting by stratification for the 'strata' variable.

AGE1

Stratified logrank using SAS:

2.8744

```
data pop1;
  set pop;
  age1=0;
  if age >85 then age1=1;
proc lifetest data=pop1 outsurv=survres;
  time stay*censor(1);
  test age1;
  strata gender;
The LIFETEST Procedure
Rank Tests for the Association of LSTAY with Covariates
Pooled over Strata
            Univariate Chi-Squares for the LOG RANK Test
                Test
                           Standard
                                                       Pr >
   Variable
               Statistic
                           Deviation
                                       Chi-Square
                                                     Chi-Square
    AGE1
                 29.1508
                             17.1941
                                          2.8744
                                                       0.0900
           Covariance Matrix for the LOG RANK Statistics
                             Variable
                                              AGE1
                             AGE1
                                           295.636
     Forward Stepwise Sequence of Chi-Squares for the LOG RANK Test
                                   Pr >
                                              Chi-Square
                                                               Pr >
Variable
                                Chi-Square
                  Chi-Square
                                               Increment
                                                              Increment
             1
```

0.0900

2.8744

0.0900

Contents

3	Comparison of Survival Curves	1
	Basis for Comparison of Survival Curves	. 1
	3.2 General Framework for Survival Analysis	. 7
	Relationships between covariates and survival outcomes	9
	3.3 Two sample tests for Comparing Survival	. 10
	3.3.1 Mantel-Haenszel Logrank test	. 11
	3.3.2 Linear Rank Tests	. 29
	3.3.3 CMH-type Logrank versus the "Linear Rank" Logrank	. 33
	3.3.4 'Wilcoxon' tests	. 43

82 CONTENTS

	3.3.5	Generalized Wilcoxon: Peto & Peto, Prentice	54
	3.3.6	The Tarone-Ware class of tests	58
	3.3.7	Which test should we use?	62
3.4	P-s	sample and stratified logrank tests	66
	3.4.1	P-sample logrank	67
	3.4.2	The Stratified Logrank	76